Dongsian "Mendong Insulin 30" listing application was accepted by the third domestic

Mendon insulin 30 injection is a premixed insulin developed by Noor and NORD, consisting of soluble mendon insulin and sperm protein meningol insulin at a ratio of 30:70.
October 2004, the original Winter Insulin 30 injection was approved in China.
there is ample evidence at home and abroad that Nora and Reed 30 have significant advantages in improving blood sugar control, reducing the risk of hypoglycemia, improving compliance, and saving medical costs, and are more suitable for patients at high risk of impaired hypoglycemia perception (IAH).
the world's largest number of diabetics, the number of people with diabetes in china in 2019 was about 116.4 million, with 35.5 million people over the age of 65, according to the International Diabetes Federation (IDF).
public data show that in 2019, China's public medical institutions diabetes drug market size of 57.16 billion yuan, while public medical institutions diabetes TOP20 products, insulin products accounted for 9, mendong insulin 30 injection sales reached 4,873 million yuan, ranking second.
2020 H1 data, Mendon Insulin 30 jumped to number one with a sales growth rate of 14.20%.
in view of the market potential of Mendong insulin 30 injections, there are currently a number of domestic enterprises layout Mendong insulin 30 injection market.
according to insight database (), in addition to the approved Ganli Pharmaceuticals, Zhuhai Federation has also submitted a listing application, Dongsan this time listed as the third domestic paragraph.
, Tonghua Dongbao, Jilin Jinsheng and Boao Bio are in the clinical trial stage, and Jiangsu Wanbang Biochemical Pharmaceutical Group is in the clinical trial application stage.